Literature DB >> 29209681

Is there a low prevalence of Helicobacter pylori infection in Jordanian patients with gastric cancer?

Rinaldo Pellicano1.   

Abstract

[No Abstract Available].

Entities:  

Mesh:

Year:  2017        PMID: 29209681      PMCID: PMC5787643          DOI: 10.15537/smj.2017.12.21309

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.484


Awad et al1 have explored the epidemiologic features of Jordanian patients with diagnosis of gastric cancer (GC) in the period January 2006 to May 2016. A total of 165 patients were included. Regarding tumor types, most of gastric malignancies were primary adenocarcinomas (62%). Regarding Helicobacter pylori (H.pylori) infection, in 129 cases, the presence of the bacterium could be assessed, with a prevalence of 49.6%. Intestinal-type and signet ring adenocarcinomas showed a prevalence of H. pylori infection of 55.6% and 48.8%, respectively.1 Helicobacter pylori is a slow-growing, micro-aerophilic, Gram-negative bacterium, usually acquired during childhood, whose natural habitat is the luminal surface of the gastric epithelium.2 Although in 1994 the International Agency for Research on Cancer classified H. pylori as a group I carcinogen, namely, a definite cause of GC, to date the bacterium is recognized as a necessary but insufficient cause of GC. This is due to the fact that such a malignancy is a complex, multifactorial disease caused by initiators and other continuator agents. Helicobacter pylori causes chronic gastric inflammation that may progress to the precancerous changes of atrophic gastritis and intestinal metaplasia.2 Several epidemiologic studies have approached the study of the relationship between H. pylori and GC. In a multicentre study, conducted in Northern Italy, we have shown that 82.3% of patients with GC versus 56.5% of controls (p<0.0001; odds ratio, 3.58; 95% confidence interval: 2.53-5.07) were seropositive for anti-H. pylori. There was no difference between intestinal-type and diffuse-type carcinoma.3 This high prevalence rate is similar to those reported by several studies.4 Considering that in Jordan previous studies have found a prevalence of H. pylori of approximately 80% in patients with dyspepsia and gastritis or peptic ulcer5 it is unexpected the low prevalence described by Awad et al in case of GC.1 It would be interesting to know how the authors could explain these differences. This would enrich their interesting findings. I would like to thank Dr Pellicano for his interesting and valuable comments and queries. Our study demonstrated that 55.6% of intestinal type and 48.8% of signet ring gastric adenocarcinomas contained Helicobacter pylori (H. pylori).1 As Pellicano et al pointed out this prevalence is less than the 80% rate of H. pylori infection in Jordanian patients reported by Bani Hani et al.6 Our rate is also less than the prevalence reported by Latif et al7 who found that 70% of Jordanian patients with acute gastritis and 73% with chronic gastritis had H. pylori. One reason for this discrepancy is the method used to detect H. pylori. We relied on hematoxylin and eosin stained slides for their detection, whereas Bani Hani et al6 used modified Giemsa stain and Latif et al7 used bacteriology as well as histological studies; these 2 methods would have increased the detection rate. However, we believe that the main reason for the discrepancy is that the population in these studies are different. Our patients had gastric cancer, some with advanced disease, whereas none of the patients in the above mentioned studies had gastric carcinoma; they suffered from gastritis or gastric or duodenal ulceration. Helicobacter pylori associated gastritis predisposes to gastric cancer through a multistep process that includes gastric atrophy and intestinal metaplasia but it is well known that during this process H. pylori disappear because atrophy and intestinal metaplasia create an unfavorable environment for H. pylori.8 Within the population of our study the prevalence of intestinal metaplasia was 34.6%, this is possibly an underestimate because sampling of the patients’ specimens was not aimed at detecting metaplasia but at detecting cancer and its stage. The 34.6% rate quoted in the study is the rate of incidentally found intestinal metaplasia foci. In summary we do not believe that the prevalence of H. pylori infection in gastric carcinoma among Jordanian patients is low. There are limitations in our study regarding detecting the actual prevalence of H. pylori due to the methodology used but also it is important to recognize that the demonstration of H. pylori after cancer development does not reflect the actual prevalence as this bacterium is expected to disappear once cancer has fully developed. University of Jordan Jordan University Hospital Amman, Jordan
  7 in total

1.  Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy.

Authors:  Giorgio Palestro; Rinaldo Pellicano; Gian Ruggero Fronda; Guido Valente; Marco De Giuli; Tito Soldati; Agostino Pugliese; Stefano Taraglio; Mauro Garino; Donata Campra; Miguel Angel Cutufia; Elena Margaria; Giancarlo Spinzi; Aldo Ferrara; Giorgio Marenco; Mario Rizzetto; Antonio Ponzetto
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Prevalence of Helicobacter pylori in Northern Jordan. Endoscopy based study.

Authors:  K E Bani-Hani; S M Hammouri
Journal:  Saudi Med J       Date:  2001-10       Impact factor: 1.484

3.  Helicobacter pylori Infection and Gastric Adenocarcinoma.

Authors:  Pelayo Correa; M Blanca Piazuelo
Journal:  US Gastroenterol Hepatol Rev       Date:  2011-06

Review 4.  A 2016 panorama of Helicobacter pylori infection: key messages for clinicians.

Authors:  Rinaldo Pellicano; Davide G Ribaldone; Sharmila Fagoonee; Marco Astegiano; Giorgio M Saracco; Francis Mégraud
Journal:  Panminerva Med       Date:  2016-12       Impact factor: 5.197

5.  Helicobacter pylori: a Jordanian study.

Authors:  A H Latif; S K Shami; R Batchoun; N Murad; O Sartawi
Journal:  Postgrad Med J       Date:  1991-11       Impact factor: 2.401

6.  Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project.

Authors:  C A González; F Megraud; A Buissonniere; L Lujan Barroso; A Agudo; E J Duell; M C Boutron-Ruault; F Clavel-Chapelon; D Palli; V Krogh; A Mattiello; R Tumino; C Sacerdote; J R Quirós; E Sanchez-Cantalejo; C Navarro; A Barricarte; M Dorronsoro; K-T Khaw; N Wareham; N E Allen; K K Tsilidis; H Bas Bueno-de-Mesquita; S M Jeurnink; M E Numans; P H M Peeters; P Lagiou; E Valanou; A Trichopoulou; R Kaaks; A Lukanova-McGregor; M M Bergman; H Boeing; J Manjer; B Lindkvist; R Stenling; G Hallmans; L M Mortensen; K Overvad; A Olsen; A Tjonneland; K Bakken; V Dumeaux; E Lund; M Jenab; I Romieu; D Michaud; T Mouw; F Carneiro; C Fenge; E Riboli
Journal:  Ann Oncol       Date:  2011-09-14       Impact factor: 32.976

7.  Epidemiologic characteristics of gastric malignancies among Jordan University Hospital patients.

Authors:  Heyam A Awad; Manar H Hajeer; Mohand W Abulihya; Mohammad A Al-Chalabi; Ali A Al Khader
Journal:  Saudi Med J       Date:  2017-09       Impact factor: 1.484

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.